Kevin Tang, a director and 10% owner of Boundless Bio, Inc. (NASDAQ:BOLD), filed a Form 4 on November 20, 2026, disclosing three open-market purchases of common stock totaling 103,612 shares across November 18, 19, and 20, 2026.

Key Highlights

  • Three consecutive purchases: Tang acquired 22,231 shares on November 18, 41,461 shares on November 19, and 39,920 shares on November 20, 2026.
  • Weighted-average prices: Shares were purchased at weighted-average prices of $2.40, $2.37, and $2.32 on each respective date, according to the filing.
  • Resulting ownership: Following the reported transactions, Tang indirectly beneficially owns 3,152,991 shares of common stock.
  • Indirect ownership structure: Shares are held indirectly through Tang Capital Partners, LP; Tang Capital Partners International, LP; Tang Capital Partners III, Inc.; and Tang Capital Partners IV, Inc.
  • Disgorgement payment: The filing states that "The Reporting Persons have delivered to the Issuer the full amount of the disgorgeable profit arising the purchases reported herein, in the amount of $226.30."
  • Dual reporting persons: The form was filed jointly by Kevin Tang and Tang Capital Management LLC, both located at 4747 Executive Drive, Suite 210, San Diego, California 92121.

Kevin Tang's Three-Day Share Purchases in Boundless Bio

According to the Form 4 filed with the SEC, Kevin Tang, identified as a director and 10% owner of Boundless Bio, Inc., made three separate open-market purchases of the company's common stock on November 18, 19, and 20, 2026. On November 18, Tang acquired 22,231 shares at a weighted-average price of $2.40, with individual transaction prices ranging from $2.39 to $2.40. On November 19, he acquired 41,461 shares at a weighted-average price of $2.37, with prices ranging from $2.35 to $2.40. On November 20, he acquired 39,920 shares at a weighted-average price of $2.32, with prices ranging from $2.30 to $2.39.

The filing discloses that all shares are held indirectly. Tang Capital Partners, LP holds 707,167 shares; Tang Capital Partners International, LP holds 1,044,076 shares; Tang Capital Partners III, Inc. holds 707,160 shares; and Tang Capital Partners IV, Inc. holds 694,588 shares. The filing states that Kevin Tang is the sole manager of Tang Capital Management, LLC, which serves as the general partner of TCP and TCPI, and that he is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP.

The filing also notes that the reporting persons delivered to the issuer a disgorgeable profit payment of $226.30 in connection with the purchases reported. The form was signed by Kevin Tang on November 20, 2026, in his individual capacity and as manager of Tang Capital Management LLC. The filing indicates that full detail on the number of shares purchased at each individual price within the stated ranges will be provided upon request to the issuer, any security holder, or the SEC staff.

What Was Disclosed

Kevin Tang and Tang Capital Management LLC reported three purchases of Boundless Bio common stock totaling 103,612 shares between November 18 and November 20, 2026, at weighted-average prices ranging from $2.32 to $2.40, bringing indirect beneficial ownership to 3,152,991 shares.